Shockwave Therapy for ED (ESWT) in Singapore: How It Works and What the Evidence Shows

Almost every treatment for erectile dysfunction is a workaround. Tablets amplify a signal for a few hours. Injections force the vascular event chemically. Vacuum devices do it mechanically. All of them are used at the moment of need, and none of them changes the tissue.

Low-intensity extracorporeal shockwave therapy, usually shortened to ESWT or Li-ESWT, is the exception. It is delivered as a course of sessions, it is not used at the time of intercourse, and its aim is to improve the penis's own blood supply so that erectile function is better between and after treatments. That difference in intent is what makes it interesting, and it is also why it needs to be judged on a different kind of evidence.

This article explains the mechanism, reviews what the trials show, and sets out who is likely to benefit. For the clinical service itself, see our ESWT treatment page.

The problem ESWT is designed to address

Most erectile dysfunction in men over forty is vascular. Arteries stiffen and narrow, the endothelium loses its capacity to produce nitric oxide on demand, and the small vessels that feed the erectile chambers deliver less blood than they used to. Our article on what causes ED covers this in detail.

PDE5 inhibitors work by preserving the downstream signal, but they need something to amplify. In men with significant vascular disease there may simply not be enough inflow capacity for the drug to work with, which is why response rates drop in long-standing diabetes and after prostate surgery. ESWT targets the supply side instead.

What shockwaves actually are

Despite the name, there is no electricity involved. A shockwave is an acoustic pressure wave, a very short, high-amplitude sound pulse. The same physics underpins lithotripsy, which has been used to break kidney stones for decades, and the tendon treatments used in sports medicine.

The critical distinction is intensity. Lithotripsy uses high-energy shockwaves specifically to fracture stone. ESWT for erectile dysfunction uses low-intensity waves, typically around a tenth of that energy, applied not to destroy tissue but to provoke a controlled biological response in it.

Mechanotransduction, in plain terms

Cells sense mechanical force and respond to it chemically. This is the same principle behind bones strengthening under load and muscles adapting to resistance training.

When low-intensity shockwaves pass through the erectile tissue, the mechanical stress on the cells triggers a cascade that has been documented in laboratory and animal studies:

• Release of angiogenic growth factors, particularly vascular endothelial growth factor, which stimulates the formation of new small blood vessels.
• Increased nitric oxide synthase activity, improving the tissue's own capacity to produce the molecule erections depend on.
• Recruitment of endothelial progenitor cells, which contribute to repair of the vessel lining.
• Improved microcirculation as new capillary networks form over the weeks following treatment.

The intended end point is not a single erection but a measurably better-perfused organ. This is why the benefit accumulates over weeks after the course finishes rather than appearing during it.

What the evidence shows

ESWT has been studied in a reasonable number of randomised, sham-controlled trials, which is the right standard for a treatment where expectation effects are strong.

The consistent findings. Meta-analyses of randomised trials have shown statistically significant improvement in erectile function scores compared with sham treatment, with the effect most reliable in men with mild to moderate vascular ED. A proportion of men who were previously non-responders to PDE5 inhibitors become responders after a course, which is clinically useful in itself.

Duration. Follow-up studies suggest benefit persisting for around six to twelve months in many responders, with some data extending further. Retreatment is possible.

The honest caveats. Trial protocols vary considerably in energy levels, number of sessions and device type, which makes pooled results harder to interpret. Some studies are small. Effect sizes are moderate rather than dramatic, and results in severe ED, long-standing poorly controlled diabetes and post-prostatectomy nerve injury are considerably less impressive. Professional guidelines generally describe the evidence as promising and recommend ESWT as an option for appropriately selected men, while noting that protocols are not yet standardised.

Anyone promising a guaranteed cure is overselling it. The realistic framing is a meaningful chance of genuine improvement in the right patient, with an excellent safety profile.

The evidence base by indication

ESWT has been studied for more than one urological indication, and the strength of evidence differs meaningfully between them, which matters because it is easy for marketing material to blur the distinction.

Vasculogenic erectile dysfunction has the strongest and most consistent evidence base of the indications discussed here. Multiple sham-controlled randomised trials and several meta-analyses report statistically significant improvement in validated erectile function questionnaires compared with placebo treatment, with the effect most reproducible in mild to moderate disease. This is the indication professional urological bodies are most comfortable describing as a reasonable option for appropriately selected patients.

PDE5 inhibitor non-response. A secondary but clinically useful finding across several trials is that a proportion of men who did not respond adequately to tablets before treatment did respond to them afterwards. This is a smaller and less consistently replicated body of evidence than the primary erectile function outcome, but it is a genuinely practical reason to consider a course before concluding that oral medication has failed for good.

Peyronie's disease, plaque-related penile curvature, has also been studied with ESWT, generally for the pain associated with the acute phase rather than for correcting curvature itself. Evidence here is considerably weaker and more mixed than for vasculogenic ED, with some trials showing pain improvement and little consistent effect on the degree of curvature. This is a different treatment goal from ED-focused ESWT and should not be conflated with it when discussing expected outcomes.

Chronic pelvic pain syndrome and chronic prostatitis have a small emerging literature using shockwave therapy directed at the pelvic floor, with early positive signals on pain scores in some studies. This remains considerably less established than the ED indication, and men considering it for this reason should understand that it is a less mature area of practice.

The overall picture is that ESWT for vascular erectile dysfunction rests on the firmest ground, while its use for other indications is plausible in principle but should be discussed as an option with more modest and less certain supporting evidence.

Who is not suitable for ESWT

Beyond the categories of men less likely to benefit, there are situations where ESWT should not be offered at all, or should only proceed after a specific issue is addressed first.

Active genital or urinary tract infection is a straightforward contraindication until treated, since the inflamed tissue is not an appropriate target and the risk of worsening local inflammation is unnecessary. Suspected or confirmed penile cancer is an absolute contraindication, and any concerning lesion needs full diagnostic assessment before any energy-based treatment is considered.

Men on therapeutic anticoagulation or with a known bleeding disorder need a specific risk discussion, since the treated tissue is vascular and, while serious bleeding has not been a notable feature of the trial literature, caution is warranted rather than assumed safety. Priapism history is a relative caution, since introducing an intervention aimed at improving blood flow in someone with a prior episode of prolonged, unwanted erection needs careful individual judgement.

Men who have not had a basic medical work-up are, in a practical sense, also not yet suitable, because ESWT treats the vascular supply rather than the range of other causes of erectile dysfunction. Undiagnosed and untreated low testosterone, uncontrolled diabetes, significant untreated depression or relationship difficulty, and medication side effects, for example from certain antihypertensives or antidepressants, are all common contributors that a course of shockwave therapy will not address. Starting ESWT before these are assessed risks spending money and time on a treatment aimed at the wrong part of the problem, which is why the assessment stage described below is not a formality to be rushed through.

Who is a good candidate

Likely to benefit:

• Mild to moderate ED of vascular origin.
• Men who respond partially to PDE5 inhibitors and want to improve their baseline.
• Men who cannot take PDE5 inhibitors, for example those on nitrates.
• Men who prefer not to depend on medication before intercourse.
• Men with early vascular ED who are also correcting risk factors.

Less likely to benefit:

• Severe ED with complete loss of erectile capability.
• Predominantly psychogenic ED, where the vascular supply is not the problem. Our article on ED and mental health covers the alternative approach.
• ED following nerve injury from radical prostatectomy, where the limiting factor is neural rather than vascular.
• Untreated low testosterone, which should be assessed first.
• Advanced diabetic ED with established fibrosis and venous leak.

Proper selection is the largest single determinant of outcome, which is why assessment before treatment matters more than the device brand.

What a course involves

Assessment first. History, examination, and blood tests covering glucose, HbA1c, lipids and morning testosterone. There is little point starting a course of shockwave therapy in a man whose real problem is undiagnosed diabetes or a contributing medication.

The sessions. Typical protocols run six to twelve sessions, once or twice weekly, over three to six weeks. Each session takes around fifteen to twenty-five minutes. A probe with coupling gel is applied to several points along the shaft and at the base of the penis, delivering a set number of pulses at each. There are no needles, no anaesthetic, and no downtime. Most men describe a mild tapping or tingling sensation rather than pain.

Afterwards. You can drive, work and exercise the same day. There is no restriction on sexual activity.

Timeline of results. Because the mechanism is tissue remodelling, nothing happens immediately. Men who respond typically notice change from around four weeks after starting, with the fuller effect at two to three months after the course ends. Assessment of response is done at that point, not during treatment.

Maintaining the result. ESWT improves blood supply; it does not stop atherosclerosis. Men who continue smoking, remain sedentary or leave their glucose uncontrolled will lose the benefit faster. Pairing the course with genuine risk factor work, as described in our article on natural approaches to ED, gives the best durability.

Safety

This is the strongest part of the ESWT case. Across the randomised trials, serious adverse events are essentially absent. There is no anaesthesia, no incision and no systemic drug exposure. Reported side effects are limited to transient mild discomfort during the session and occasional temporary redness.

Contraindications are few: active genital infection, penile cancer, and caution in men on anticoagulants or with bleeding disorders.

How it compares with other options

Option	Acts when	Treats the cause	Ongoing use needed
PDE5 inhibitors	On demand, per encounter	No, compensates	Yes
ESWT	Course of sessions, effect builds	Targets vascular supply	Periodic retreatment
Vacuum device	At time of use	No	Yes
Injections	At time of use	No	Yes
Lifestyle and risk factor control	Continuous	Yes	Permanent
Penile implant	Permanent	Replaces mechanism	No

ESWT and lifestyle change are the two options aimed at the underlying vascular problem, and they work well together. ESWT also combines safely with PDE5 inhibitors during a course.

A word on devices sold for home use

Consumer devices marketed as home shockwave machines are generally acoustic wave or vibration devices operating at far lower energies than the clinical equipment used in trials, and they are not the same treatment. Evidence for them is absent, and using one without an assessment means the underlying cause of the ED goes uninvestigated.

ESWT in Singapore

Hisential offers shockwave therapy to men from across Singapore as part of a full erectile dysfunction assessment rather than as a standalone package. That means the underlying cause is identified first and treatment is recommended only where the vascular picture suggests it is likely to help. Consultation is from S$50 after GST before investigations or treatment. The clinic is on Orchard Road near Orchard MRT, with a private waiting area, and sessions are scheduled to fit around working hours.

Frequently asked questions

Does shockwave therapy for ED hurt?

Almost never. Low-intensity ESWT is delivered at roughly a tenth of the energy used in kidney stone treatment. Most men describe a mild tapping sensation. No anaesthetic is needed and you can resume normal activity immediately.

How many sessions will I need?

Most protocols involve six to twelve sessions over three to six weeks, delivered once or twice a week. The exact number depends on the protocol used and the severity of the vascular problem.

How long do the results last?

Published follow-up suggests benefit lasting around six to twelve months in men who respond, sometimes longer. Because the treatment does not halt underlying vascular disease, durability depends heavily on controlling risk factors such as smoking, glucose and blood pressure. Retreatment is possible.

Will it work if tablets have not worked for me?

Sometimes, and this is one of the more useful findings in the literature. A proportion of previous PDE5 non-responders become responders after a course. It is less likely to help if the cause is nerve injury or severe long-standing diabetic disease.

Is ESWT a cure for erectile dysfunction?

No. It is a treatment that can produce genuine, lasting improvement in appropriately selected men with vascular ED. Any clinic promising a guaranteed cure is going beyond the evidence.

Can I combine it with ED medication?

Yes. Many men continue PDE5 inhibitors during the course and find they need a lower dose, or need them less often, afterwards.

References

• European Association of Urology, Guidelines on Sexual and Reproductive Health.
• Clavijo RI et al., Low-intensity shockwave therapy for erectile dysfunction, systematic review and meta-analysis.
• Vardi Y et al., Sham-controlled trial of low-intensity extracorporeal shockwave therapy for erectile dysfunction.
• Sokolakis I, Hatzichristodoulou G, Clinical studies on low-intensity extracorporeal shockwave therapy for erectile dysfunction, systematic review.